


## OVrSeq Analysis Report for TCGA-04-1331

2023-12-04


The vulnerability map indicate based on BRCAness probability and CYT to C1QA ratio (C2C) indications with a high vulnerability (score) for response to combination immunotherapy with PARPi and immune checkpoint inhibitors.



### Patient values



Feature	Value
BRCAness status	1 (0.82)
Tumor immune phenotype	Desert
Molecular subtypes	PRO
BRCAness immunetype	noBRIT
Vulnerability score	2.39
Immunophenoscore	1
CYT to C1QA ratio (C2C)	0.15
Angiogenesis Score	2

Marker gene expression and reference values from TCGA-OV [median (Q1-Q3)].



Feature	Patient Value	TCGA IQR
CD274	1.21	1.32 (0.87-1.86)
GZMB	2.15	2.55 (1.62-3.51)
PRF1	0.63	1.73 (1.15-2.50)
C1QA	6.11	7.35 (6.41-8.18)
CD8A	1.10	1.90 (1.17-2.65)
IDO1	4.11	4.16 (2.80-5.45)
FOXP3	1.75	1.94 (1.32-2.52)
TREM2	3.61	4.83 (3.76-5.64)
STAT1	7.27	7.01 (6.21-7.55)
HLA-DRA	5.21	7.26 (6.30-8.00)
CXCL10	4.72	6.38 (5.03-7.54)

Enrichment of gene signatures or pathways (ssGSEA) and estimated immune cell fraction (quanTIseq)



\*Enrichment score is standardized to min-max values from TCGA-OV reference.